Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962893 | 0.94 | TLR7 (0.65) | TLR7IL6 | |
| SCHEMBL20764372 | 0.93 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL22503727 | 0.92 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL22794062 | 0.90 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL22341167 | 0.89 | TLR7 (0.72) | TLR7IL6 | |
| SCHEMBL22130940 | 0.86 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL22130937 | 0.84 | TLR7 (0.74) | TLR7IL6 | |
| SCHEMBL4465749 | 0.84 | TLR7 (0.54) | TLR7IL6 | |
| SCHEMBL4467239 | 0.84 | TLR7 (0.56) | TLR7IL6 | |
| SCHEMBL20764366 | 0.83 | TLR7 (0.58) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| WO-2022188740-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | FCGR1A, FCGR2A, TLR3 | TLR7 28/4885IL6 3324/4885 |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | FCGR1A, FCGR2A, TLR3 | TLR7 28/4885IL6 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.